Aliskiren is a direct renin inhibitor, blocking the first and rate-limiting step of the renin-angiotensin-aldosterone system (RAAS). This action prevents the conversion of angiotensinogen to angiotensin I, leading to decreased levels of angiotensin II, vasodilation, and ultimately, lower blood pressure. While RAAS modulation is a key area of aging research, Aliskiren is used clinically for hypertension and has not demonstrated unique healthspan benefits beyond blood pressure control.
Verdict
A targeted hypertension drug with no proven unique healthspan benefits.
HEALTHSPAN IMPACT
Experimental
RISK LEVEL
Moderate
EVIDENCE GRADE
A
MONTHLY COST
$40 - $80
Protocol
- The standard starting dose is 150 mg taken orally once per day.
- The dose may be increased to 300 mg once per day for additional blood pressure control.
Flags
- Black box warning: Can cause fetal injury and death; discontinue if pregnancy is detected.
- Should not be combined with ACE inhibitors or ARBs in patients with diabetes due to increased risk of adverse outcomes.
- Risk of hyperkalemia (high potassium), especially when combined with other RAAS inhibitors or in patients with renal impairment.
- May cause severe allergic reactions, including angioedema.
- Common side effects include diarrhea, cough, dizziness, and headache.